The Company presented interim results from the TAMARACK study at the European Society for Medical Oncology (ESMO) Congress in September 2024 and expects to have mature median radiographic ...
Net cash provided by operating activities was $203.7 million, and non-GAAP free cash flow was $161.7 million for the third quarter of 2024. As of September 30, 2024, we no longer include acquisition ...